PhD Scientific Days 2017

Oral Presentations: Oncology

Immune checkpoint markers in pregnancy-related – and in early-onset breast cancer: A comparative study

Előadó neve

Dr. Ács, Balázs, PhD

Előadó munkahelye

2nd Department of Pathology, Semmelweis University

Előadó telefonszáma

+36203365253

Előadó e-mail címe

acs.balazs.se@gmail.com

Az előadás címe

Immune checkpoint markers in pregnancy-related – and in early-onset breast cancer: A comparative study

Szerző(k) neve és munkahelye

Balázs Ács 1, Lilla Madaras 1, Anna-MáriaTőkés 1, Attila Kristóf Kovács 1, Ede Birtalan 2, Magdolna Dank 3, A. Marcell Szász 1,3, Janina Kulka 1
1 2nd Department of Pathology, Semmelweis University
2 Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Semmelweis University
3 Department of Clinical Oncology, Semmelweis University

Szekció

Oral Presentations: Oncology

Data of the presenter

Doctoral School: Pathological Sciences
Program: Alteration of cell and extracellular matrix in cardiovascular- and certain neoplastic diseases. Experimental and diagnostic pathomorphological examinations.
Supervisor: A. Marcell Szasz
E-mail address: acs.balazs.se@gmail.com

Text of the abstract

Introduction: Immune-checkpoint markers (ICM) could be promising therapeutic targets, though their expression have been investigated neither in pregnancy-related breast cancer (PRBC), nor in young women with non-PRBC (YWBC).
Aims: Our aim in this study was to compare the immunohistochemical (IHC) expression of PD-1, PD-L1 and CTLA-4 of PRBC and YWBC, and their prognosis prediction potential was correlated to that of conventional clinicopathological factors.
Method: Twenty-one PRBC cases were paired with 21 YWBC in this matched case-control study. ICM were evaluated with IHC on whole slides using the following antibodies: PD-1 (NAT-105), PD-L1 (28-8) and CTLA-4 (F-8). IHC score was defined as the percentage of positive cells, assessed separately among tumor cells, intratumoral lymphocytes and peritumoral lymphocytes. The optimal threshold for ICM was assessed by ROC analysis. KM plots with log-rank test and Cox regression analysis were to correlate ICM with outcome (DFS=Disease-free survival, OS=Overall survival).
Results: The optimal threshold of PD-L1 expression of tumor cells occurred at 10% for OS (AUC:0.847, p=0.009), and at 1% for DFS (AUC:0.795, p=0.010). For PD-L1 expression on intratumoral lymphocytes, the optimal cut-off value was 1% (AUC:0.763, p=0.048). Considering PD-1, PD-L1 and CTLA-4 expression, no significant difference occurred between PRBC and YWBC (p>0.05 for all comparisons). PD-1, PD-L1 expressed on peritumoral lymphocytes and CTLA-4 failed, but PD-L1 expressed on tumor cells and on intratumoral lymphocytes was suitable to distinguish patient cohorts with different OS and DFS. (p≤0.011 for all comparisons). Higher PD-L1 expression was associated with poor prognosis. PD-L1 expressed on tumor cells represented an independent association with OS (p=0.023) and DFS (p=0.032).
Conclusion: Our results suggest that PRBC and YWBC do not differ in the expression of PD-1, PD-L1 and CTLA-4. However, our findings emphasize the relevance of PD-L1 expression in early-onset breast cancer, as an independent negative predictor of prognosis.

Kind

Szabad

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

1013

Authors (legacy)

Balázs Ács 1, Lilla Madaras 1, Anna-MáriaTőkés 1, Attila Kristóf Kovács 1, Ede Birtalan 2, Magdolna Dank 3, A. Marcell Szász 1,3, Janina Kulka 1
1 2nd Department of Pathology, Semmelweis University
2 Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Semmelweis University
3 Department of Clinical Oncology, Semmelweis University